XAV-939 No Further a Mystery
Patients were stratified into four groups according to pretreatment position, that's untreated, dealt with with alkylating brokers, handled with and attentive to FAMP with or without the need of alkylating brokers but relapsing, and addressed with and refractory to FAMP with or with out alkylating agents.fifty six Additionally, the TNKS inhibitor G